FindTrial
Sign In

To assess the need for biopsy using MRI and PETCT for prostatic disease

Predicting the need for biopsy using F-18 PSMA PET CT evaluation in cases of PIRADS 3 lesions - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055419
Enrollment
43
Registered
2023-07-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C61- Malignant neoplasm of prostate

Interventions

Control Intervention1: NIL: NIL

Sponsors

Kasturba Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. PIRADS 3 LESIONS as defined by multiparametric MRI. 2. Time-interval between MRI and PET CT is 6 weeks. 3. Availability of histopathology report.

Exclusion criteria

Exclusion criteria: 1. patients with prior radiotherapy, hormonal therapy, and transurethral resection of the prostate. 2. missed clinical data. 3. second primary malignancies. 4. prostatitis and prostatic abscess. 5. patients who refuse to give consent/are not willing to the procedure.

Design outcomes

Primary

MeasureTime frame
Correlation between PIRADS scoring, PSMA PET CT & histopathological findings.Timepoint: After 1 year(31st July,2024)—

Secondary

MeasureTime frame
Compilation of data to assess the accuracy of imaging methods used & usefulness in avoiding unnecessary biopsiesTimepoint: 31st JULY, 2025—

Countries

India

Contacts

Public ContactDr Anand Venugopal

Kasturba Medical College

anandvmanipal@gmail.com9845085668

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026